

POLARIS QCDR IN COLLABORATION WITH THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – 2022 MEASURE SPECIFICATIONS

POLAR1

Measure #	POLAR1
Measure Title	Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents - Avoidance of Overuse (Lower Score - Better).
Measure Description	Percentage of cancer patients aged 18 years and older treated with low- or minimal-emetic-risk antineoplastic agents who are administered inappropriate pre-treatment antiemetic therapy.
Denominator Exclusion	None
Denominator Exceptions	None
Denominator	All final reports for DEXA scans. Defined as: Patients aged 40 to 90 on the date of service AND Patient procedure during the performance period (CPT): 77080, 77081, 77085 or 77086 AND Diagnosis of Osteopenia documented with ICD10 code: M85.8, M85.80, M85.811, M85.812, M85.819, M85.821, M85.822, M85.829, M85.831, M85.832, M85.839, M85.841, M85.842, M85.849, M85.851, M85.852, M85.859, M85.861, M85.862, M85.869, M85.871, M85.872, M85.879, M85.88, M85.89, M85.9
Numerator	Numerator 1: Patients who are administered prior to treatment an NK1 receptor antagonist or olanzapine Numerator 2: Patients who are administered prior to treatment an NK1 receptor antagonist, 5-HT3 receptor antagonist, olanzapine, or dexamethasone
Numerator Exclusions	None
Number of Performance Rates to be calculated and submitted	1
Inverse Status	Yes
Proportional, CV, Ratio Status	Proportional
Risk Adjusted, if applicable	No
High Priority measure	Yes
Measure type	Process
NQS Domain	Effective Clinical Care
NQF ID	N/A
Meaningful Measure Area	Appropriate use of Healthcare
Care Setting (s)	Ambulatory Care: Clinician Office/Clinic
Telehealth, if applicable	No

Copyright: ©2021 American Society of Clinical Oncology. All Rights Reserved. The American Society for Clinical Oncology (ASCO) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of ASCO, its members and the Polaris Qualified Clinical Data Registry for the purposes specified herein and for other ASCO purposes. It may not be used by other parties except with prior written approval of ASCO. Contact measurement@asco.org for licensing this measure.